https://www.optimumcomms.com/wp-content/uploads/2024/03/Asgard_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-06-03 09:06:222025-06-03 09:06:22Asgard Therapeutics strengthens its Board of Directors and Advisory Board with leading experts in drug development and cancer immunotherapy
https://www.optimumcomms.com/wp-content/uploads/2024/03/Asgard_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-06-03 09:06:222025-06-03 09:06:22Asgard Therapeutics strengthens its Board of Directors and Advisory Board with leading experts in drug development and cancer immunotherapy
Amber Implants Announces Successful One-Year Follow-Up Data in First-in-Human Clinical of VCFix® Spinal System
One-year follow-up data from first-in-human trial shows significant…

iOnctura bolsters leadership team with new appointments
Steven Sciuto joins as Chief Financial Officer (CFO) bringing…

Bionical Emas and Pharma Resources Announce Exclusive Global Clinical Trial Supply Partnership
Strategic agreement secures access to essential oncology injectables…

STORM Therapeutics Announces First Patient Dosed in Clinical Collaboration to Evaluate STC-15 in Combination with LOQTORZI® and Appointment of Atif Abbas, M.D., as Chief Medical Officer
STC-15 has demonstrated durable clinical activity and tolerability…

Nucleome Therapeutics appoints Bhavna Hunjan as Chief Business Officer
Oxford, UK, 27 May 2025 – Nucleome Therapeutics (‘Nucleome’…

Heidelberg Pharma Announces First Patient Dosed in Phase I Study of Amanitin-based ADC Candidate HDP-102 for Non-Hodgkin Lymphoma
Ladenburg, Germany, 27 May 2025 – Heidelberg Pharma AG (FSE:…

Poolbeg Pharma plc – Poolbeg granted FDA Orphan Drug Designation for POLB 001
27 May 2025 - Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the…

Poolbeg Pharma plc – Annual Report, AGM Notice & Circular
27 May 2025 - Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the…

Heidelberg Pharma Announces First Patient Dosed in Phase I Study of Amanitin-based ADC Candidate HDP-102 for Non-Hodgkin Lymphoma
Ladenburg, Germany, 27 May 2025 – Heidelberg Pharma AG (FSE:…

Novo Nordisk Foundation enters into strategic framework agreement with the World Health Organization (WHO) to advance global health
With the agreement, the Foundation expands its existing collaboration…

Poolbeg Pharma plc – Proposed Retail Offer to raise up to £100,000
Poolbeg Pharma plc (AIM: POLB, 'Poolbeg Pharma' or the 'Company'),…

Poolbeg Pharma plc – Proposed Fundraising to raise approximately £4.1 million, Launch of Placing via accelerated bookbuild and Notice of General Meeting
Poolbeg Pharma plc (AIM: POLB, 'Poolbeg Pharma' or the 'Company'),…

Poolbeg Pharma plc – Results for the year ended 31 December 2024
20 May 2025- Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company'), a…

Lars Rebien Sørensen to join the board of directors of Novo Nordisk A/S
Novo Nordisk A/S announced earlier today that Lars Rebien Sørensen,…

Novo Holdings appoints four new members to its Board of Directors further strengthening global perspectives and strategic capabilities
May 15, 2025 – Novo Holdings is pleased to announce the appointments…
We’d love to hear from you
For more information about Optimum Strategic Communications, please get in touch.
Optimum Strategic Communications’ specialist team has an in-depth understanding of how to communicate complex science to investors and corporate stakeholders. Optimum helps life science companies on their journey as they grow and has been trusted by hundreds of healthcare clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York